Edward Pershing - Sep 23, 2022 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role: Director
Signature: /s/ Edward Pershing
Stock symbol: PVCT
Transactions as of: Sep 23, 2022
Transactions value $: $242,500
Form type: 4
Date filed: 10/28/2022, 01:31 PM
Previous filing: Oct 5, 2023
Next filing: Nov 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PVCT	8% Unsecured Convertible Promissory Note due 2023	Award	$75K	$75K	Sep 23, 2022	Series D-1 Convertible Preferred Stock	26.2K	$2.86	Direct	F1, F2
transaction	PVCT	8% Unsecured Convertible Promissory Note due 2023	Award	$110K	$185K	Sep 30, 2022	Series D-1 Convertible Preferred Stock	38.4K	$2.86	Direct	F1, F2
transaction	PVCT	8% Unsecured Convertible Promissory Note due 2023	Award	$50K	$235K	Oct 14, 2022	Series D-1 Convertible Preferred Stock	17.5K	$2.86	Direct	F1, F2
transaction	PVCT	8% Unsecured Convertible Promissory Note due 2023	Award	$7.5K	$243K	Oct 27, 2022	Series D-1 Convertible Preferred Stock	2.62K	$2.86	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.
F2	Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

Content

The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.

Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.